A Klaes1, E Reckziegel2, M C Franca3, T J R Rezende4, L M Vedolin5, L B Jardim6, J A Saute7. 1. From the Departments of Radiology (A.K., L.M.V.). 2. Medical Genetics Services (E.R., L.B.J., J.A.M.S.), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 3. Departments of Neurology (M.C.F., T.J.R.R.). 4. Departments of Neurology (M.C.F., T.J.R.R.) Cosmic Rays and Chronology (T.J.R.R.), Universidade Estadual de Campinas, Campinas, Brazil. 5. From the Departments of Radiology (A.K., L.M.V.) Department of Internal Medicine (L.M.V., L.B.J.). 6. Medical Genetics Services (E.R., L.B.J., J.A.M.S.), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil Department of Internal Medicine (L.M.V., L.B.J.) Postgraduate Program in Medicine: Medical Sciences (L.B.J.), Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. 7. Medical Genetics Services (E.R., L.B.J., J.A.M.S.), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil jsaute@hcpa.edu.br.
Abstract
BACKGROUND AND PURPOSE: Polyglutamine expansion spinocerebellar ataxias are autosomal dominant slowly progressive neurodegenerative diseases with no current treatment. MR imaging is the best-studied surrogate biomarker candidate for polyglutamine expansion spinocerebellar ataxias, though with conflicting results. We aimed to review quantitative central nervous system MR imaging technique findings in patients with polyglutamine expansion spinocerebellar ataxias and correlations with well-established clinical and molecular disease markers. MATERIALS AND METHODS: We searched MEDLINE, LILACS, and Cochrane data bases of clinical trials between January 1995 and January 2016, for quantitative MR imaging volumetric approaches, MR spectroscopy, diffusion tensor imaging, or other quantitative techniques, comparing patients with polyglutamine expansion spinocerebellar ataxias (SCAs) with controls. Pertinent details for each study regarding participants, imaging methods, and results were extracted. RESULTS: After reviewing the 706 results, 18 studies were suitable for inclusion: 2 studies in SCA1, 1 in SCA2, 15 in SCA3, 1 in SCA7, 1 in SCA1 and SCA6 presymptomatic carriers, and none in SCA17 and dentatorubropallidoluysian atrophy. Cerebellar hemispheres and vermis, whole brain stem, midbrain, pons, medulla oblongata, cervical spine, striatum, and thalamus presented significant atrophy in SCA3. The caudate, putamen and whole brain stem presented similar sensitivity to change compared with ataxia scales after 2 years of follow-up in a single prospective study in SCA3. MR spectroscopy and DTI showed abnormalities only in cross-sectional studies in SCA3. Results from single studies in other polyglutamine expansion spinocerebellar ataxias should be replicated in different cohorts. CONCLUSIONS: Additional cross-sectional and prospective volumetric analysis, MR spectroscopy, and DTI studies are necessary in polyglutamine expansion spinocerebellar ataxias. The properties of preclinical disease biomarkers (presymptomatic) of MR imaging should be targeted in future studies.
BACKGROUND AND PURPOSE:Polyglutamine expansion spinocerebellar ataxias are autosomal dominant slowly progressive neurodegenerative diseases with no current treatment. MR imaging is the best-studied surrogate biomarker candidate for polyglutamine expansion spinocerebellar ataxias, though with conflicting results. We aimed to review quantitative central nervous system MR imaging technique findings in patients with polyglutamine expansion spinocerebellar ataxias and correlations with well-established clinical and molecular disease markers. MATERIALS AND METHODS: We searched MEDLINE, LILACS, and Cochrane data bases of clinical trials between January 1995 and January 2016, for quantitative MR imaging volumetric approaches, MR spectroscopy, diffusion tensor imaging, or other quantitative techniques, comparing patients with polyglutamine expansion spinocerebellar ataxias (SCAs) with controls. Pertinent details for each study regarding participants, imaging methods, and results were extracted. RESULTS: After reviewing the 706 results, 18 studies were suitable for inclusion: 2 studies in SCA1, 1 in SCA2, 15 in SCA3, 1 in SCA7, 1 in SCA1 and SCA6 presymptomatic carriers, and none in SCA17 and dentatorubropallidoluysian atrophy. Cerebellar hemispheres and vermis, whole brain stem, midbrain, pons, medulla oblongata, cervical spine, striatum, and thalamus presented significant atrophy in SCA3. The caudate, putamen and whole brain stem presented similar sensitivity to change compared with ataxia scales after 2 years of follow-up in a single prospective study in SCA3. MR spectroscopy and DTI showed abnormalities only in cross-sectional studies in SCA3. Results from single studies in other polyglutamine expansion spinocerebellar ataxias should be replicated in different cohorts. CONCLUSIONS: Additional cross-sectional and prospective volumetric analysis, MR spectroscopy, and DTI studies are necessary in polyglutamine expansion spinocerebellar ataxias. The properties of preclinical disease biomarkers (presymptomatic) of MR imaging should be targeted in future studies.
Authors: H Jacobi; P Bauer; P Giunti; R Labrum; M G Sweeney; P Charles; A Dürr; C Marelli; C Globas; C Linnemann; L Schöls; M Rakowicz; R Rola; E Zdzienicka; T Schmitz-Hübsch; R Fancellu; C Mariotti; C Tomasello; L Baliko; B Melegh; A Filla; C Rinaldi; B P van de Warrenburg; C C P Verstappen; S Szymanski; J Berciano; J Infante; D Timmann; S Boesch; S Hering; C Depondt; M Pandolfo; J-S Kang; S Ratzka; J Schulz; S Tezenas du Montcel; T Klockgether Journal: Neurology Date: 2011-08-10 Impact factor: 9.910
Authors: Camila N Fahl; Lucas Melo T Branco; Felipe P G Bergo; Anelyssa D'Abreu; Iscia Lopes-Cendes; Marcondes C França Journal: Cerebellum Date: 2015-04 Impact factor: 3.847
Authors: T Schmitz-Hübsch; S Tezenas du Montcel; L Baliko; J Berciano; S Boesch; C Depondt; P Giunti; C Globas; J Infante; J-S Kang; B Kremer; C Mariotti; B Melegh; M Pandolfo; M Rakowicz; P Ribai; R Rola; L Schöls; S Szymanski; B P van de Warrenburg; A Dürr; T Klockgether; Roberto Fancellu Journal: Neurology Date: 2006-06-13 Impact factor: 9.910
Authors: Isaac M Adanyeguh; Pierre-Gilles Henry; Tra M Nguyen; Daisy Rinaldi; Celine Jauffret; Romain Valabregue; Uzay E Emir; Dinesh K Deelchand; Alexis Brice; Lynn E Eberly; Gülin Öz; Alexandra Durr; Fanny Mochel Journal: Mov Disord Date: 2015-03-15 Impact factor: 10.338
Authors: Herminia D Rosas; Gheorghe Doros; Sona Gevorkian; Keith Malarick; Martin Reuter; Jean-Philippe Coutu; Tyler D Triggs; Paul J Wilkens; Wayne Matson; David H Salat; Steven M Hersch Journal: Neurology Date: 2014-02-07 Impact factor: 9.910
Authors: Alex Tiburtino Meira; Walter Oleschko Arruda; Sergio Eiji Ono; Arnolfo de Carvalho Neto; Salmo Raskin; Carlos Henrique F Camargo; Hélio Afonso G Teive Journal: Tremor Other Hyperkinet Mov (N Y) Date: 2019-09-26
Authors: Gabriel Vasata Furtado; Camila Maria de Oliveira; Gabriela Bolzan; Jonas Alex Morales Saute; Maria Luiza Saraiva-Pereira; Laura Bannach Jardim Journal: Genet Mol Biol Date: 2019-06-10 Impact factor: 1.771
Authors: Ricardo Mouro Pinto; Larissa Arning; James V Giordano; Pedram Razghandi; Marissa A Andrew; Tammy Gillis; Kevin Correia; Jayalakshmi S Mysore; Debora-M Grote Urtubey; Constanze R Parwez; Sarah M von Hein; H Brent Clark; Huu Phuc Nguyen; Eckart Förster; Allison Beller; Suman Jayadaev; C Dirk Keene; Thomas D Bird; Diane Lucente; Jean-Paul Vonsattel; Harry Orr; Carsten Saft; Elisabeth Petrasch-Parwez; Vanessa C Wheeler Journal: Hum Mol Genet Date: 2020-08-29 Impact factor: 6.150